The FDA decision on Acer Therapeutics Inc.’s (ACER) ACER-001 for the treatment of patients with Urea Cycle Disorders is expected on June 5, 2022.ACER-001, a re-purposed sodium phenylbutyrate, designed for oral administration, consists of a core center, a layer of active drug, and a taste-masked coating designed to avoid the bitter taste of sodium phenylbutyrate in the mouth.If approved, ACER-001 will have to compete with Horizon Pharma’s Ravicti and Buphenyl. Ravicti generated sales of $291.9 million and Buphenyl had sales of $7.9 million in 2021.Acer is developing ACER-001 in collaboration with RELIEF THERAPEUTICS Holding SA (RLFTF.OB).Acer has the rights to develop and commercialize ACER-001 in the U.S., Canada, Brazil, Turkey and Japan while Relief has retained rights to the drug for the rest of the world. ACER closed Thursday’s (May 26, 2022) trading at $2.18.